EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction

About this update from Genmab A/s

[{"type":"list","items":[{"val":[{"type":"text","content":"Genmab has entered into a definitive agreement to acquire Merus in an all-cash transaction for a total consideration of USD 8.0 billion, making it one of the largest acquisitions of a European biotech company to date","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"Merus is a clinical-stage oncology company developing bi/tri-specific antibodies, with a pipeline including petosemtamab for head and neck squamous cell carcinoma and other malignancies","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"EQT Life Sciences has been an investor in Merus since 2010, supporting the Company at board level in its growth from a start-up company to a NASDAQ-listed clinical-stage biotech with multiple late-stage oncology assets","length":218,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":619,"olType":false},{"type":"text","content":"STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- EQT Life Sciences, a leading European life sciences venture capital firm, is pleased to share that Genmab (CPH: GMAB) has entered into a definitive agreement to acquire its portfolio company Merus (NASDAQ: MRUS) for a total consideration of USD 8.0 billion. This transaction represents one of the largest M&A deals in European biotech and underscores the value of Merus' innovative clinical pipeline addressing significant unmet needs in oncology.","length":497,"tagName":"p"},{"type":"text","content":"Merus, based in Utrecht, the Netherlands, is a clinical-stage biotech company developing innovative bispecific and trispecific antibody therapeutics for the treatment of cancer. The company's products include petosemtamab, in development for head and neck squamous cell carcinoma and other malignancies, and zenocutuzumab, an approved product for patients with NRG1 fusion–driven tumors such as pancreatic and lung cancers. Despite significant advances in oncology, patients with these tumor types continue to face poor prognoses and limited treatment options, underscoring the urgent need for more effective therapies.","length":623,"tagName":"p"},{"type":"text","content":"Over the past year, Merus' lead program petosemtamab, has delivered best-in-class Phase 2 results in both first-line and later-line head and neck cancer, significantly outperforming historical benchmarks and positioning itself a...

More updates from Genmab A/s